 OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to predicted 24-month survival probability 10 vs 10-29.9 vs 30, age 65 years vs 65 years, and prior history of arterial events i.e., cardiac ischemiainfarction, CNS cerebrovascular ischemia, peripheral arterial ischemia, or CNS hemorrhage yes vs no. Patients are randomized to 1 of 2 treatment arms. 